

Additional File 3. Comparison of plasma immune checkpoint proteins between males who spontaneously cleared HCV (SC group) versus controls (C group).

Marker	Un-adjusted			Adjusted		
	AMR (95%CI)	<i>p</i> -value	<i>q</i> -value	aAMR (95%CI)	<i>p</i> -value	<i>q</i> -value
BTLA	1.48 (1.19–1.85)	0.002	0.007	1.49 (1.18–1.88)	0.003	0.014
CD137(4-1BB)	1.56 (1.19–2.03)	0.003	0.010	1.53 (1.17–2.02)	0.005	0.017
CD152(CTLA4)	1.20 (0.79–1.83)	0.392	0.478	1.19 (0.77–1.83)	0.441	0.537
CD27	1.54 (0.10–2.33)	0.055	0.091	1.53 (0.99–2.37)	0.070	0.122
CD28	1.45 (0.94–2.22)	0.105	0.155	1.40 (0.90–2.20)	0.149	0.209
CD80	1.50 (1.15–1.96)	0.006	0.016	1.48 (1.12–1.96)	0.011	0.031
GITR	1.73 (1.26–2.38)	0.002	0.008	1.73 (1.24–2.41)	0.004	0.014
HVEM	1.36 (1.09–1.69)	0.011	0.026	1.38 (1.12–1.69)	0.006	0.018
IDO	1.66 (1.27–2.16)	0.001	0.007	1.65 (1.25–2.16)	0.002	0.014
LAG-3	1.66 (1.25–2.21)	0.002	0.007	1.64 (1.22–2.20)	0.003	0.014
PD-1	1.57 (1.25–1.98)	<0.001	0.007	1.60 (1.26–2.04)	0.001	0.014
PD-L1	1.50 (1.11–2.02)	0.012	0.026	1.55 (1.13–2.12)	0.013	0.032
PD-L2	1.56 (1.22–1.99)	0.001	0.007	1.59 (1.22–2.06)	0.002	0.014
TIM-3	1.63 (1.26–2.10)	0.001	0.007	1.40 (1.07–1.83)	0.025	0.059
Arginase	1.22 (1.02–1.46)	0.038	0.071	1.23 (1.02–1.50)	0.045	0.097
E-Cadherin	1.90 (1.24–2.91)	0.006	0.016	1.56 (0.98–2.48)	0.075	0.124
MICA	1.40 (1.05–1.87)	0.032	0.063	1.37 (1.00–1.87)	0.059	0.118
MICB	1.28 (1.01–1.62)	0.052	0.091	1.28 (1.00–1.64)	0.066	0.122
NT5E(CD73)	1.09 (0.81–1.46)	0.572	0.618	1.06 (0.78–1.45)	0.702	0.760
Nectin-2(CD112)	1.12 (0.75–1.67)	0.574	0.618	1.08 (0.72–1.63)	0.706	0.760
PVR(CD155)	1.31 (0.93–1.84)	0.133	0.187	1.33 (0.95–1.87)	0.113	0.166
Perforin	1.26 (0.91–1.96)	0.318	0.412	1.32 (0.84–2.07)	0.243	0.325
Siglec-7	1.18 (0.85–1.65)	0.324	0.412	1.15 (0.84–1.57)	0.389	0.495
Siglec-9	1.87 (1.31–2.66)	0.002	0.008	1.87 (1.29–2.70)	0.003	0.014
Tactile(CD96)	1.13 (0.76–1.68)	0.552	0.618	1.14 (0.75–1.73)	0.549	0.640
ULBP-1	0.98 (0.62–1.56)	0.947	0.947	1.05 (0.68–1.63)	0.817	0.845
ULBP-3	1.33 (1.00–1.78)	0.063	0.098	1.30 (0.96–1.76)	0.108	0.166
ULBP-4	1.02 (0.84–1.15)	0.804	0.834	1.02 (0.83–1.27)	0.845	0.845

Statistics: Data were calculated by Generalized Linear Models (GLM) with a gamma distribution (log-link). Multivariable models were adjusted by age, IL28 genotype, and AST, previously selected by a stepwise method (forward) (see **Results Section**). The *q*-values represent *p*-values corrected for multiple testing using the False Discovery Rate (FDR). Significant differences are shown in bold.

Abbreviations: AMR, arithmetic mean ratio; aAMR, adjusted AMR; 95%CI, 95% of confidence interval; *p*, level of significance; *q*, corrected level of significance; BTLA, B and T lymphocyte attenuator; CD, cluster of differentiation; GITR, glucocorticoid-induced TNFR-related; HVEM, herpesvirus entry mediator; IDO, indoleamine 2,3-dioxygenase; LAG-3, lymphocyte activation gene-3; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PD-L2, programmed death-ligand 2; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; MICA, MHC class I chain-related gene A; MICB, MHC class I chain-related gene B; NT5E, ecto-5'-nucleotidase; PVR, poliovirus receptor; Siglec, sialic acid-binding immunoglobulin-type lectin; ULBP, human ligand for binding protein.